Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Invivyd, Inc. has received an average analyst recommendation of "Moderate Buy" with six brokerages covering the stock, including one sell rating and one strong buy rating.
• The company's quarterly earnings report showed an EPS of ($0.12), missing estimates, with revenue of $11.79 million compared to expectations of $23.16 million.
• Institutional investors hold 70.36% of Invivyd's stock, with significant recent acquisitions and increases from firms like Vanguard and Jane Street Group.

Shares of Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $4.8875.

IVVD has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Invivyd in a report on Wednesday, August 27th. Cantor Fitzgerald started coverage on shares of Invivyd in a research note on Monday. They set an "overweight" rating and a $10.00 price target for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Invivyd in a report on Saturday, September 27th. Finally, D. Boral Capital cut their target price on shares of Invivyd from $3.00 to $1.00 and set a "buy" rating for the company in a research note on Monday, August 25th.

Invivyd Price Performance

NASDAQ IVVD opened at $1.16 on Monday. The company's 50 day simple moving average is $0.96 and its 200 day simple moving average is $0.79. The firm has a market capitalization of $139.37 million, a PE ratio of -1.26 and a beta of 0.57. Invivyd has a 12 month low of $0.35 and a 12 month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The business had revenue of $11.79 million during the quarter, compared to analyst estimates of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. Sell-side analysts anticipate that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Jill Andersen sold 49,402 shares of Invivyd stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total transaction of $28,159.14. Following the sale, the insider directly owned 84,446 shares in the company, valued at $48,134.22. This trade represents a 36.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 277,654 shares of company stock worth $167,215. 25.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IVVD. Catalyst Funds Management Pty Ltd acquired a new position in shares of Invivyd in the 2nd quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC lifted its position in shares of Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock worth $29,000 after purchasing an additional 28,146 shares during the period. Jane Street Group LLC increased its stake in shares of Invivyd by 290.5% in the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after acquiring an additional 87,358 shares in the last quarter. Nuveen LLC bought a new stake in shares of Invivyd in the 1st quarter valued at $65,000. Finally, XTX Topco Ltd bought a new stake in shares of Invivyd in the 1st quarter valued at $66,000. Institutional investors and hedge funds own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.